Aerie Pharmaceuticals (NSDQ:AERI) said today that it inked a collaborative R&D and licensing agreement with DSM to develop an implantable drug-delivery system for patients with glaucoma and other retinal diseases.
DSM has reportedly developed an injectable drug-delivery fiber using polyesteramide polymers that has proven successful in preclinical work with Aerie’s compounds.
A product candidate developed by the Irvine, Calif.-based company, AR-13154, successfully decreased lesion size in a preclinical model of wet age-related macular degeneration at levels comparable to market-leading products, according to Aerie.
The company also reported that the therapy reduced neovascularization in a preclinical model of proliferative diabetic retinopathy.
“A key to unlocking the potential of AR-13154 and related Aerie-owned compounds for the treatment of retinal diseases is the identification of the appropriate technology to achieve longer-term sustained delivery of our small molecules to the back of the eye,” chairman & CEO Vicente Anido said in prepared remarks. “We are hopeful that DSM’s PEA technology may prove to be that technology.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.